TXNIP and liver disorder: The miR-17, which can suppress NLRP3 inflammasome activation by targeting TXNIP expression, is abundant in AMSC-Exo cargo; this clearly indicates that AMSC-Exo-based therapy may be a promising approach for treating TXNIP/NLRP3 inflammasome-related inflammatory liver diseases [109].